Azar Abbas

Azar Abbas

Auto-generated profile, based on publicly available information

Azar Abbas

Institute of Medicine, Shenzhen Institute of Advanced Technology, Shenzhen, Guangdong, People’s Republic of China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
AUaftab ullah
aftab ullah
MKMarina Khan
Marina Khan
YZYibang Zhang
Yibang Zhang
Muhammad ShafiqMuhammad Shafiq
Muhammad Shafiq
MUMohsan Ullah
Mohsan Ullah
YDYong Diao
Yong Diao
The effective clinical translation of messenger RNA (mRNA), small interfering RNA (siRNA), and microRNA (miRNA) for therapeutic purposes hinges on the development of efficient delivery systems. Key challenges include their susceptibility to degradation, limited cellular uptake, and inefficient intracellular release. Polymeric drug conjugates (PDCs) offer a promising solution, combining the benefits of polymeric carriers and therapeutic agents for targeted delivery and treatment. This comprehensive review explores the clinical translation of nucleic acid therapeutics, focusing on polymeric drug conjugates. It investigates how these conjugates address delivery obstacles, enhance systemic circulation, reduce immunogenicity, and provide controlled release, improving safety profiles. The review delves into the conjugation strategies, preparation methods, and various classes of PDCs, as well as strategic design, highlighting their role in nucleic acid delivery. Applications of PDCs in treating diseases such as cancer, immune disorders, and fibrosis are also discussed. Despite significant advancements, challenges in clinical adoption persist. The review concludes with insights into future directions for this transformative technology, underscoring the potential of PDCs to advance nucleic acid-based therapies and combat infectious diseases significantly.

1 July 2021 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
AUaftab ullah
aftab ullah
GCGang Chen
Gang Chen
AHAbid Hussain
Abid Hussain
HKHanif Khan
Hanif Khan
AAAzar Abbas
Azar Abbas
DLDaojun Liu
Daojun Liu
Background: Liver fibrosis is a chronic liver disease with excessive production of extracellular matrix proteins, leading to cirrhosis, hepatocellular carcinoma, and death. Purpose: This study aimed at the development of a novel derivative of polyethyleneimine (PEI) that can effectively deliver transforming growth factor β (TGFβ) siRNA and inhibit chemokine receptor 4 (CXCR4) for TGFβ silencing and CXCR4 Inhibition, respectively, to treat CCl4-induced liver fibrosis in a mouse model. Methods: Cyclam-modified PEI (PEI-Cyclam) was synthesized by incorporating cyclam moiety into PEI by nucleophilic substitution reaction. Gel electrophoresis confirmed the PEI-Cyclam polyplex formation and stability against RNAase and serum degradation. Transmission electron microscopy and zeta sizer were employed for the morphology, particle size, and zeta potential, respectively. The gene silencing and CXCR4 targeting abilities of PEI-Cyclam polyplex were evaluated by luciferase and CXCR4 redistribution assays, respectively. The histological and immunohistochemical staining determined the anti-fibrotic activity of PEI-Cyclam polyplex. The TGFβ silencing of PEI-Cyclam polyplex was authenticated by Western blotting. Results: The 1H NMR of PEI-Cyclam exhibited successful incorporation of cyclam content onto PEI. The PEI-Cyclam polyplex displayed spherical morphology, positive surface charge, and stability against RNAse and serum degradation. Cyclam modification decreased the cytotoxicity and demonstrated CXCR4 antagonistic and luciferase gene silencing efficiency. PEI-Cyclam/siTGFβ polyplexes decreased inflammation, collagen deposition, apoptosis, and cell proliferation, thus ameliorating liver fibrosis. Also, PEI-Cyclam/siTGFβ polyplex significantly downregulated α-smooth muscle actin, TGFβ, and collagen type III. Conclusion: Our findings validate the feasibility of using PEI-Cyclam as a siRNA delivery vector for simultaneous TGFβ siRNA delivery and CXCR4 inhibition for the combined anti-fibrotic effects in a setting of CCl4-induced liver fibrosis.

7 July 2022 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
AAAzar Abbas
Azar Abbas
PJPeng Jun
Peng Jun
JYJiang Yuan Yuan
Jiang Yuan Yuan
LSLi Sun
Li Sun
JJJinwei Jiang
Jinwei Jiang
SYShengtao Yuan
Shengtao Yuan

1 April 2026 in International Journal of Nanomedicine
Verified
Journal Article
Open access
AUaftab ullah
aftab ullah
MKMarina Khan
Marina Khan
YZYibang Zhang
Yibang Zhang
Muhammad ShafiqMuhammad Shafiq
Muhammad Shafiq
MUMohsan Ullah
Mohsan Ullah
YDYong Diao
Yong Diao
CXCR4 plays a pivotal role in liver fibrosis (LF) by mediating the activation of hepatic stellate cells (HSCs), which contribute to extracellular matrix (ECM) deposition and scar formation. The CXCR4/CXCL12 axis is essential in fibrogenesis, promoting HSCs activation, inflammation, and angiogenesis, which exacerbates fibrosis and creates an environment conducive to hepatocellular carcinoma (HCC) development. In HCC, CXCR4 signaling supports tumor cell proliferation, survival, and metastasis, linking chronic liver injury to cancer progression. Recent advancements in targeted drug delivery have facilitated the development of CXCR4-targeted therapies, improving treatment efficacy while minimizing systemic toxicity. This review examines the interactions between CXCR4 and its ligand CXCL12, the associated signaling pathways, and their role in LF and HCC. Furthermore, it explores CXCR4 as a therapeutic target, focusing on CXCR4 blockers, peptide inhibitors, and gene silencing/editing strategies. The review also highlights various CXCR4-targeted nano therapeutic strategies, such as liposomes, lipid NPs, microbubbles, polymeric NPs incorporating siRNA, miRNA, small molecules, peptides etc for the management of LF and HCC. Additionally, the review addresses the clinical progress of monoclonal antibodies, small molecules, and peptides targeting CXCR4 in both preclinical and clinical trials. Challenges and future directions of CXCR4-targeted nanotherapeutic are also discussed. In conclusion, this review emphasizes the therapeutic potential of CXCR4-targeted nanotherapeutic strategies for combating LF and HCC.

1 June 2026 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
AUaftab ullah
aftab ullah
GCGang Chen
Gang Chen
AHAbid Hussain
Abid Hussain
HKHanif Khan
Hanif Khan
AAAzar Abbas
Azar Abbas
DLDaojun Liu
Daojun Liu
Retraction for the article Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis

7 September 2021 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
AUaftab ullah
aftab ullah
GCGang Chen
Gang Chen
AHAbid Hussain
Abid Hussain
HKHanif Khan
Hanif Khan
AAAzar Abbas
Azar Abbas
DLDaojun Liu
Daojun Liu
Corrigendum for the article Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis